U.K. Deal Reached For 5-Year Price Cap On State’s Branded Drug Regulation
This article was originally published in The Pink Sheet Daily
The first-ever cap on U.K. National Health Service drug price increases will last five years. Pharma firms reluctantly agreed to the restrictions, but say they are excessive and further undermine Britain’s attractiveness as a place to conduct drug R&D.
You may also be interested in...
Prices may decrease, but at least wider societal benefits are to be included in NICE’s assessment in the U.K.’s new value-based pricing (VBP) scheme for new pharmaceuticals, a change long demanded by critics of the health technology assessment body.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.